Second-line with paclitaxel and carboplatin for recurrent disease following first paclitaxel and platinum compounds in ovarian carcinoma

Objective: The combination of paclitaxel and platinum compounds is considered the best first-line regimen for advanced ovarian carcinoma. The purpose of this study was to evaluate a paclitaxel and carboplatin combination in pretreated patients who recurred within 24 months after a complete clinical response with the same regimen used as first-line chemotherapy.

Methods: 18 patients were included in this study. Second-line chemotherapy consisted of paclitaxel, 175 mg/m2 as a 3-hour infusion, and carboplatin AUC 6 every 21 days.

Results: Among 15 evaluable patients, eight (53%) complete and five (34%) partial responses were observed, while two (13%) patients had stable disease (SD). The response rate was 67% among patients with measurable disease and 52% for evaluable disease. The median progression-free interval after second-line chemotherapy was 8.3 months. The median progression-free interval for patients with measurable disease was 8.6 months and for evaluable disease it was 7.9 months. Seven (46%) of 15 patients have developed recurrence after second-line chemotherapy with paclitaxel and carboplatin with a median time to recurrence of 9.8 months.

Conclusion: Paclitaxel 175 mg/m2 and carboplatin AUC 6 as second-line chemotherapy in this sensitive population is effective in terms of response rate and progression-free interval.

Ovarian cancer; Paclitaxel; Carboplatin; Chemotherapy

[1] Boring C. C., Squires T. S., Tong. T.: "Cancer statistics, 1991" Cancer J. Clin., 1991, 41, 19.

[2] Gore M. E., Fryatt I., Wiltshaw E., Dawson T.:'Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds". Gynecol. Oneal., 1990, 36, 207.

[3] Thipgen J. T., Blessing J. A., Ball H., Hummel S. J., Barrett R. J "Phase II trial of paclitaxel in patients with progressive ovarian carcinoma, after platinum-based chemotherapy. Gynecologic Oncology Group study". J. Clin. Oneal., 1994, 12, 1748.

[4] Gershenson D. M., Kavanagh T. T., Copeland U., Stringer A., Morris M., Won M.: "Retreatment of patients with recurrent epithelial ovanian cancer with platin-based chemotherapy" Obstet. Gynecol., 1989, 73, 798.

[5] Markinan M., Hakes T., Barakat R., Curfin J., Almadrones L., Hoskins W.: "Follow-up of Memorial Sloan Kettering Cancer Center patients treated on NCI treatment Referral Center Protocol 9103: Paclitaxel in refractory ovarian cancer". J. Clin. Oncol., 1996, 14, 796.

[6] Rustin G. J. S., Nelstrop A. E., McClean P., Brady M. F., McGuire W. P., Hoskins W. J. et al.: "Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125". J. Clin. Oneal., 1996, 14, 1545.

[7] Ozols R. F.: "Chemotherapeutic dose intensity in ovarian cancer" Adv. Oncol., 1995, 11, 24.

[8] Rowinsky E. K., Donchower R. C.: "Paclitaxel (Taxol)". N. Eng. J. Med., 1995, 332, 1004.

[9] Thigpen J. T., Blessing J. A., Bali H., llnmmel S. J.: "Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: GOG-Study". I. Clin. Oncol., 1994, 12, 1748.

[10] Heisenhauer E. A., Ten Bokkel Huinink W. W. et al.: "EuropeanCanadian randomized trial of paelitaxel in relapsed ovarian cancer: High dose vs low-dose and long vs short infusion". J. Clin. Oneal., 1994, 12, 2654.

[11] Sarosy G., Kolin E., Stone D. A.: "Phase I study of taxol and granulocyte colony stimulating factor in patients with refractory ovarian cancer". J. Clin. Oneal., 1992, 10, 1165.

[12] Cavaletti G., Bogliun G., Marzorati L., Zincone A., Marzola M., Colomba N., Tredici G.: "Peripheral neurotoxicity of taxol in patients previously treated with cis-platin". Cancer, 1995, 75, 1141.

[13] Schiff P. B., Fant J., Horowitz S. B.: "Promotion of microtubule assembly in vitro by taxol". Nature, 1979, 277, 655.

[14] Kumar N.: "Taxol induced polymerization of purified tubulin". J Biol. Chem., 1981, 256, 10435.

[15] Uslu R., Bonavida B.: "Role of free radicals in the synergy ach,eved by treatment with both TNF-a and CDDP on human ovarian carcinoma cells". Cancer, 1996, 77, 725.

[16] Uslu R., Bonavida B.: "Free radical dependent and independent pathways of CDDP mediated cytotoxicity and apoptosis in ovarian tumor cell lines". Int. J. Oneal., 1995, 6, 1003.

[17] Markman M. et al.: "Current status and future directions of plallnum/paclitaxel-based chemotherapy of ovarian cancer". Semin Oneal., 1997, 24 (Suppl. II), 24.

[18] Sevin B. U., Perras J.P.:'Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer". Am. J. Obstet GYMOJ, 1997, 176 (4), 759.

[19] Trimble E., Adams M., Vena D., Hawkins M. J., Friedinan M. A., Fishermmi J. S. et al.: "Paclitavol for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to Nationale Cancer Institute Treatment Referral Center 9103". J. Clin. Oneal., 1993, 11, 2405.